Kiniksa(US:KNSA)2026-01-12 12:00ARCALYST Performance and Market - ARCALYST has achieved approximately $1.5 billion in net revenue since its launch and is on track to become a blockbuster[7] - ARCALYST has only about 18% penetration into the multiple recurrence population, indicating continued growth potential[7] - The company anticipates ARCALYST revenue between $900 million and $920 million in 2026[7] - Approximately 80% of patients on ARCALYST were prescribed the drug when they had 2 or more recurrences, while about 20% were prescribed on their 1st recurrence[27] - In Q4 2025, ARCALYST net revenue reached $202.1 million, representing approximately 65% year-over-year growth[32] Financial Position and Pipeline - The company reported approximately $414 million in cash reserves at the end of 2025[8] - KPL-387, is currently in a Phase 2/3 trial, with Phase 2 data expected in the second half of 2026[7] - KPL-1161 Phase 1 first-in-human trial is expected to initiate by the end of 2026[7] KPL-387 Development - Approximately 75% of recurrent pericarditis patients prefer the KPL-387 target profile over available commercial and investigational therapies[58] - Approximately 75% of ARCALYST-naïve patients would be more willing to take an injectable therapy if presented in an autoinjector[59] - Approximately 70% of healthcare providers report a high likelihood of prescribing KPL-387 for new patients[60]